Navigation Links
DUSA Pharmaceuticals Named to Deloitte's 2010 Technology Fast 500 List of Fastest Growing Companies in North America

WILMINGTON, Mass., Oct. 26 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology announced today that it has been named to Deloitte's 2010 Technology Fast 500 list.  For the third consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America.  Rankings are based on percentage of fiscal year revenue growth during the period 2005-2009.  DUSA grew annual revenues by 163% during this period.

"DUSA is honored to receive this recognition from Deloitte for the third year in a row," said Bob Doman, DUSA's President and Chief Executive Officer.  "This is a testament to all of the dedicated DUSA employees who, over the years, have contributed to making our Levulan® Photodynamic Therapy (PDT) one of the fastest growing procedures in dermatology."

Levulan PDT is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.  AKs are the most frequently diagnosed skin disease by U.S. dermatologists with over 5 million treatment visits per year.  Through the first six months of 2010, U.S. Levulan revenue grew 34% over the prior year six months.

Technology Fast 500 Selection and Qualifying Criteria

Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.  This ranking is compiled from nominations submitted directly to the Technology Fast 500 website, and public company database research.  Technology Fast 500 award winners for 2010 are selected based on percentage fiscal year revenue growth during the five year period from 2005 to 2009.

To be considered, Technology Fast 500 entrants must meet the following criteria:

  • Must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues.
  • Base-year operating revenues must be at least $50,000 USD or CD, and current-year operating revenues must be at least $5 million USD or CD.
  • Be in business a minimum of five years.
  • Be headquartered in North America.

About Actinic Keratoses

Actinic keratoses are rough-textured, dry, scaly patches on the skin caused by excessive exposure to ultraviolet light, such as sunlight.  They occur most frequently on sun exposed areas such as the face, scalp, ears, neck, hands and arms.  They form on the outermost layer of skin and they can range in color from skin toned to reddish brown.  They can also range in size from as small as a pinhead to larger than a quarter.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products.  Levulan® Kerastick® for topical solution plus DUSA's BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.  DUSA also markets other dermatology products, including the BLU-U without Levulan and ClindaReach®.  DUSA is based in Wilmington, Mass.  Please visit our website at

SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast
2. Strativa Pharmaceuticals Signs Agreement With Swedish Orphan Biovitrum Regarding Nascobal®
3. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
4. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
5. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
6. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
7. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
8. Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
9. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
10. Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President
11. MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
Post Your Comments:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):